Summary
The effects of the aldose reductase inhibitor, sorbinil, on symptomatic symmetrical diabetic polyneuropathy were studied during a 6-month period in a double-blind parallel group placebo-controlled trial. Twenty-seven patients received sorbinil and 28 placebo. The patients were assessed by clinical examination, neurophysiological measurements, sensory threshold determinations and tests of autonomic nerve function. No major clinical benefit was seen in the sorbiniltreated patients and no differences in sensory thresholds were observed. In three out of nine neurophysiological tests (motor nerve conduction velocity of the posterior tibial nerve, F-wave latency and sensory distal latency of the ulnar nerve) and one out of five tests of autonomic nerve function (heart rate variation during deep breathing) significant differences between the patient groups evolved in favour of sorbinil treatment. An overall evaluation of the temporal development of these and remaining neurophysiological and autonomic variables suggested a small but significant benefit from sorbinil treatment. There was no evidence of continuing improvement throughout the treatment period and beneficial effects observed were no greater than those seen in previous trials of considerably shorter treatment periods. It is concluded that sorbinil treatment results in some improvement in peripheral nerve function in symptomatic diabetic polyneuropathy, but that the long-term effect may be of limited value.
Article PDF
Similar content being viewed by others
References
Thomas PK, Eliasson SG (1984) Diabetic neuropathy. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R (eds) Peripheral neuropathy. WB Saunders, Philadelphia, pp 1773–1810
Pirart J (1977) Diabète et complications dégénératives présentation d'une étude prospective portant sur 4400 cas observés entre 1947 et 1973. Diabète Metab (Paris) 3: 97–107, 173–182, 245–256
Gabbay KH, Merola LO, Field RA (1966) Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 151: 209–210
Handelsman DJ, Turtle JR (1981) Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 30: 459–464
Fagius J, Jameson S (1981) Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy — a clinical and neurophysiological study. J Neurol Neurosurg Psychiatr 44: 991–1001
Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Lian K-Y, Gabbay KH, Rubenstein AH, Porte D Jr (1983) Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. New Engl J Med 308: 119–125
Young RJ, Ewing DJ, Clarke BF (1983) A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 32: 938–942
Jaspan J, Maselli R, Herold K, Bartkus C (1983) Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet 2: 758–762
Schouten JA, Hermans JJ, Popp-Snijders C, Boot H, van den Akker J, van der Veen EA (1984) A 3-month, placebo-controlled, efficacy study of sorbinil for diabetic neuropathy. Diabetologia 27: 329A
Peterson MJ, Sarges R, Aldinger CE, MacDonald DP (1979) CP- 45, 634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. Metabolism 28 (Suppl): 456–461
Agardh C-D, Rosén I, Scherstén B (1983) Improvement of peripheral nerve function after institution of insulin treatment in diabetes mellitus. Acta Med Scand 213: 283–297
Foulds G, O'Brien MM, Bianchine JR, Gabbay KH (1981) Kinetics of an orally absorbed aldose reductase inhibitor, sorbinil. Clin Pharmacol Ther 30: 693–700
Bergström J, Lindblom U, Norée L-O (1975) Preservation of peripheral nerve function in severe uremia during treatment with low protein high calorie diet and surplus of essential amino acids. Acta Neurol Scand 51: 99–109
Lachman T, Shahani BT, Young RR (1980) Late responses as aids to diagnosis in peripheral neuropathy. J Neurol Neurosurg Psychiatr 43: 156–162
Goldberg JM, Lindblom U (1979) Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psychiatr 42: 793–80
Fruhstorfer H, Lindblom U, Schmidt WG (1976) Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatr 39: 1071–1075
Fagius J, Wallin BG (1980) Sympathetic reflex latencies and conduction velocities in patients with polyneuropathy. J Neurol Sci 47: 449–461
Mackay JD, Page MMcB, Cambridge J, Watkins PJ (1980) Diabetic autonomic neuropathy. The diagnostic value of heart rate monitoring. Diabetologia 18: 471–478
Pfeifer MA, Cook D, Brodsky J, Tice D, Reenan A, Swedine S, Halter JB, Porte D Jr (1982) Quantitative evaluation of cardiac parasympathetic activity in normal and diabetic man. Diabetes 31: 339–345
Wålinder O (1980) A rapid microchromatographic method for determination of hemoglobin A1. Upsala J Med Sci 85: 151–158
Fagius J, Wahren LK (1981) Variability of sensory threshold determination in clinical use. J Neurol Sci 51: 11–27
Halar EM, DeLisa JA, Brozovich FV (1980) Nerve conduction velocity: Relationship of skin, subcutaneous and intramuscular temperatures. Arch Phys Med Rehab 61: 199–203
Mayer JH, Tomlinson DR (1983) Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myoinositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia 25: 433–438
Finegold D, Lattimer SA, Nolle S, Bernstein M, Greene DA (1983) Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy. Diabetes 32: 988–992
Yue DK, Hanwell MA, Satchell PM, Turtle JR (1982) The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes 31: 789–794
Tomlinson DR, Moriarty RJ, Mayer JH (1984) Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor sorbinil. Diabetes 33: 470–476
Clarke BF, Ewing DJ, Campbell IW (1979) Diabetic autonomic neuropathy. Diabetologia 17: 195–212
Cicmir I, Kashiwagi S, Berger H, Koschinsky T, Gries FA (1983) Improvement of autonomic nerve functions after one year of continuous subcutaneous insulin infusion. Diabetologia 25: 147 (Abstract)
Sachse G, Neuzner J, Federlin K (1983) Long-term effect of continuous subcutaneous insulin infusion therapy on the autonomic diabetic neuropathy of the cardiovascular system. Diabetologia 25: 191 (Abstract)
Gabbay KH (1973) Role of sorbitol pathway in neuropathy. In: Camerini-Dávalos RA, Cole HS (eds) Vascular and neurological changes in early diabetes. Academic Press, New York, pp 417–424
Clements RS Jr (1982) Myoinositol metabolism in diabetic neuropathy. In: Goto Y, Horiuchi A, Kogure K (eds) Diabetic neuropathy. Excerpta Medica, Amsterdam, pp 19–25
Winegrad AI, Simmons DA, Martin DB (1983) Has one diabetic complication been explained? New Engl J Med 308: 152–154
Vlassara H, Brownlee M, Cerami A (1981) Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci 78: 5190–5192
Tuck RR, Schmelzer JD, Low PA (1984) Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107: 935–950
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fagius, J., Brattberg, A., Jameson, S. et al. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 28, 323–329 (1985). https://doi.org/10.1007/BF00283137
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00283137